GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » NxStage Medical Inc (NAS:NXTM) » Definitions » 5-Year RORE %

NxStage Medical (NxStage Medical) 5-Year RORE % : 0.00% (As of Sep. 2018)


View and export this data going back to 2005. Start your Free Trial

What is NxStage Medical 5-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. NxStage Medical's 5-Year RORE % for the quarter that ended in Sep. 2018 was 0.00%.

The industry rank for NxStage Medical's 5-Year RORE % or its related term are showing as below:

NXTM's 5-Year RORE % is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 0.27
* Ranked among companies with meaningful 5-Year RORE % only.

NxStage Medical 5-Year RORE % Historical Data

The historical data trend for NxStage Medical's 5-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

NxStage Medical 5-Year RORE % Chart

NxStage Medical Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17
5-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

NxStage Medical Quarterly Data
Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18
5-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of NxStage Medical's 5-Year RORE %

For the Medical Instruments & Supplies subindustry, NxStage Medical's 5-Year RORE %, along with its competitors' market caps and 5-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


NxStage Medical's 5-Year RORE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, NxStage Medical's 5-Year RORE % distribution charts can be found below:

* The bar in red indicates where NxStage Medical's 5-Year RORE % falls into.



NxStage Medical 5-Year RORE % Calculation

NxStage Medical's 5-Year RORE % for the quarter that ended in Sep. 2018 is calculated as:

5-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 5-year -Cumulative Dividends per Share for 5-year )
=( -0.08--0.41 )/( -1.073-0 )
=0.33/-1.073
=-30.75 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 5-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Sep. 2018 and 5-year before.


NxStage Medical  (NAS:NXTM) 5-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 5-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


NxStage Medical 5-Year RORE % Related Terms

Thank you for viewing the detailed overview of NxStage Medical's 5-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


NxStage Medical (NxStage Medical) Business Description

Traded in Other Exchanges
N/A
Address
NxStage Medical develops and manufactures products and services for patients with chronic or acute kidney failure. The firm operates in three segments: System One, In-Center, and Services. The System One segment contributes the majority of revenue. It sells and rents the System One portable hemodialysis systems and related consumable products for home and critical care hemodialysis treatments. The In-Center segment sells blood tubing sets and needles for hemodialysis, primarily to dialysis clinics. This business has a high degree of customer concentration. The Services business provides dialysis to customers at NxStage Kidney Care dialysis centers. NxStage generates the majority of its revenue in the United States.
Executives
Earl R Lewis director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Craig W Moore director C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843
Jeffrey H Burbank director, officer: Chief Executive Officer NXSTAGE MEDICAL INC, 439 SOUTH UNION STREET 5TH FLOOR, LAWRENCE MA 01843
James J Peters director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Heyward R Donigan director 452 DISCOVERY ROAD, VIRGINIA BEACH VA 23451
Jean K Mixer director C/O NXSTAGE MEDICAL, INC., 350 MERRIMACK STREET, LAWRENCE MA 01843
Kevin Hershberger officer: Chief Accounting Officer 350 MERRIMACK STREET, LAWRENCE MA 01843
Philippe O. Chambon director C/O NEW LEAF VENTURE PARTNERS, 7 TIMES SQUARE, SUITE 3502, NEW YORK NY 10036
Deerfield Management Company, L.p. (series C) 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
Deerfield Mgmt L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Partners, L.p. 10 percent owner, other: Possible Member of 10% Group 345 PARK AVENUE SOUTH, 12TH FLOOR, NEW YORK NY 10010
James E Flynn 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017
Deerfield Special Situations International Master Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017

NxStage Medical (NxStage Medical) Headlines

From GuruFocus

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,000 Shares

By GuruFocus Research GuruFocus Editor 07-15-2010

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,000 Shares

By GuruFocus Research GuruFocus Editor 08-19-2010

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 13,000 Shares

By GuruFocus Research GuruFocus Editor 10-13-2010

B. Braun to Acquire Bloodlines Business of NxStage Medical, Inc.

By Marketwired Marketwired 07-19-2018

NxStage Medical Inc. (NXTM) President & CEO Jeffrey H Burbank sells 20,000 Shares

By GuruFocus Research GuruFocus Editor 03-18-2011